Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncolytics Biotech Inc. -- Ignore unavailable to you. Want to Upgrade?

To: geoffb_si who wrote (99)	5/7/2003 9:51:18 PM
From: Cal Gary	Respond to of 103

Oncolytics resumes Reolysin phase I brain cancer trial Oncolytics Biotech Inc ONC Shares issued 22,145,284 May 6 close $2.55 Wed 7 May 2003 News Release Mr. Matthew Coffey reports ONCOLYTICS BIOTECH INC. REPORTS ENROLLMENT HAS RESUMED IN PHASE I MALIGNANT GLIOMA STUDY Enrolment has resumed in the phase I component of its clinical study examining the use of Reolysin in the treatment of recurrent malignant glioma, the most aggressive form of brain cancer. Changes to the clinical protocol were suggested by an independent data safety monitoring board, the study investigators and Oncolytics, to enhance the measurement of the safety and efficacy of Reolysin in the intended patient population in future studies. These changes have now been reviewed and approved by Health Canada. Determination of the safety of Reolysin is the primary purpose of the phase I study. The study is examining the use of a single, intratumoural injection of Reolysin, delivered using imaging-guided surgery, in patients with malignant glioma that has recurred despite other treatments, including surgery and radiation therapy. After treatment with Reolysin, the phase I patients are monitored and evaluated for safety for a period of six months. The company previously reported that Reolysin appeared to be well tolerated when surgically delivered into the brain during the treatment of the first six patients enrolled in the study. Four of the six treated patients were alive at the conclusion of their six-month safety followups. Three of these four patients continue to be followed with survival times currently ranging between 7 and 10 months posttreatment. WARNING: The company relies upon litigation protection for "forward-looking" statements. (c) Copyright 2003 Canjex Publishing Ltd. stockwatch.com